

Figure S1. Relative miR-508-3p levels in ovarian cancer cells (A) HeyA8, (B) SKOV3 and (C) A2780 transfected with miR-508-3p or miR-ctrl analyzed by reverse transcription-quantitative PCR and normalized to U6. Wilcoxon test was used to analyze the data. \*\*P<0.01. miR, microRNA; ctrl, control.




Table SI. Associations between patient clinicopathological characteristics and the expression of miR-508-3p in ovarian cancer.

Characteristic	N (130)	miR-508-3p		$\chi^2$ P-value
		Low	High	
Age, years				0.598
<59	65	29	36	
$\geq$ 59	65	32	33	
Grade <sup>b</sup>				0.549
Low	33	14	19	
High	97	47	50	
FIGO stage <sup>b</sup>				0.028 <sup>a</sup>
I+II	40	13	27	
III+IV	90	48	42	
Residual disease, cm				0.307
$\leq$ 1	95	42	53	
>1	35	19	16	
Ascites cytology				0.105
Negative	84	35	49	
Positive	46	26	20	

<sup>a</sup>P<0.05. <sup>b</sup>FIGO staging system (2013). miR, microRNA.

Table SII. Associations between patient clinicopathological characteristics and the expression of CCNA2 in ovarian cancer.

Characteristic	N (130)	CCNA2		$\chi^2$ P-value
		Low	High	
Age, years				0.587
<59	65	42	23	
$\geq$ 59	65	32	26	
Grade <sup>a</sup>				0.516
Low	33	19	14	
High	97	62	35	
FIGO stage <sup>a</sup>				0.415
I+II	40	27	13	
III+IV	90	54	36	
Residual disease, cm				0.252
$\leq$ 1	95	62	33	
>1	35	19	16	
Ascites cytology				0.802
Negative	84	53	31	
Positive	46	28	18	

<sup>a</sup>FIGO staging system (2013). CCNA2, cyclin A2.

Table SIII. Associations between patient clinicopathological characteristics and the expression of MMP7 in ovarian cancer.

Characteristic	N (130)	MMP7		$\chi^2$ P-value
		Low	High	
Age, years				0.079
<59	65	38	27	
$\geq$ 59	65	28	37	
Grade <sup>a</sup>				0.921
Low	33	17	16	
High	97	49	48	
FIGO stage <sup>a</sup>				0.520
I+II	40	22	18	
III+IV	90	44	46	
Residual disease, cm				0.484
$\leq$ 1	95	50	45	
>1	35	16	19	
Ascites cytology				0.219
Negative	84	46	38	
Positive	46	20	26	

<sup>a</sup>FIGO staging system (2013). MMP7, matrix metalloproteinase 7.